Adaptive Biotechnologies Corporation (NASDAQ:ADPT – Get Free Report) insider Francis Lo sold 39,741 shares of the stock in a transaction on Thursday, June 4th. The stock was sold at an average price of $17.49, for a total transaction of $695,070.09. Following the sale, the insider directly owned 250,934 shares of the company’s stock, valued at $4,388,835.66. This represents a 13.67% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Francis Lo also recently made the following trade(s):
- On Wednesday, April 8th, Francis Lo sold 22,564 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $15.07, for a total transaction of $340,039.48.
- On Wednesday, March 11th, Francis Lo sold 30,593 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $14.08, for a total transaction of $430,749.44.
Adaptive Biotechnologies Trading Down 1.2%
Shares of ADPT stock traded down $0.20 during trading hours on Monday, hitting $16.70. 1,749,340 shares of the company were exchanged, compared to its average volume of 1,691,541. The business has a 50 day moving average of $14.22 and a two-hundred day moving average of $15.65. Adaptive Biotechnologies Corporation has a 52 week low of $9.90 and a 52 week high of $20.76. The company has a market capitalization of $2.67 billion, a PE ratio of -50.61 and a beta of 2.16.
Institutional Inflows and Outflows
A number of hedge funds have recently added to or reduced their stakes in the business. Westfield Capital Management Co. LP bought a new position in shares of Adaptive Biotechnologies in the 4th quarter valued at about $65,942,000. Price T Rowe Associates Inc. MD grew its position in shares of Adaptive Biotechnologies by 303.4% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 4,387,361 shares of the company’s stock valued at $71,252,000 after acquiring an additional 3,299,635 shares during the period. Ameriprise Financial Inc. grew its position in shares of Adaptive Biotechnologies by 84.3% in the 3rd quarter. Ameriprise Financial Inc. now owns 5,971,706 shares of the company’s stock valued at $89,337,000 after acquiring an additional 2,731,648 shares during the period. Invesco Ltd. grew its position in shares of Adaptive Biotechnologies by 248.8% in the 4th quarter. Invesco Ltd. now owns 3,107,653 shares of the company’s stock valued at $50,468,000 after acquiring an additional 2,216,595 shares during the period. Finally, Arrowstreet Capital Limited Partnership grew its position in shares of Adaptive Biotechnologies by 544.0% in the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 2,441,402 shares of the company’s stock valued at $36,523,000 after acquiring an additional 2,062,282 shares during the period. Institutional investors own 99.17% of the company’s stock.
Analyst Upgrades and Downgrades
Several equities research analysts have recently issued reports on the stock. Wall Street Zen downgraded shares of Adaptive Biotechnologies from a “buy” rating to a “hold” rating in a research report on Saturday, March 7th. Weiss Ratings reissued a “sell (d-)” rating on shares of Adaptive Biotechnologies in a research report on Monday, April 20th. BTIG Research reaffirmed a “buy” rating and issued a $22.00 target price on shares of Adaptive Biotechnologies in a research report on Wednesday, May 6th. Guggenheim reaffirmed a “buy” rating and issued a $21.00 target price on shares of Adaptive Biotechnologies in a research report on Wednesday, May 6th. Finally, JPMorgan Chase & Co. decreased their target price on shares of Adaptive Biotechnologies from $21.00 to $19.00 and set an “overweight” rating for the company in a research report on Wednesday, May 6th. Six analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Adaptive Biotechnologies presently has a consensus rating of “Moderate Buy” and an average price target of $19.57.
Get Our Latest Stock Analysis on Adaptive Biotechnologies
About Adaptive Biotechnologies
Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.
The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.
Featured Stories
- Five stocks we like better than Adaptive Biotechnologies
- 3 Stocks With Fresh Catalysts to Watch Before the July 4
- Amprius Insiders Are Selling: Should Investors Be Worried?
- A Weaker Dollar Could Put These 3 Industrial Stocks Back in Focus
- A Market Rotation Toward Quality Will Benefit These 3 ETFs
Receive News & Ratings for Adaptive Biotechnologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptive Biotechnologies and related companies with MarketBeat.com's FREE daily email newsletter.
